JP7074677B2 - Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤 - Google Patents

Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤 Download PDF

Info

Publication number
JP7074677B2
JP7074677B2 JP2018542140A JP2018542140A JP7074677B2 JP 7074677 B2 JP7074677 B2 JP 7074677B2 JP 2018542140 A JP2018542140 A JP 2018542140A JP 2018542140 A JP2018542140 A JP 2018542140A JP 7074677 B2 JP7074677 B2 JP 7074677B2
Authority
JP
Japan
Prior art keywords
simethicone
dry suspension
tecovirimat
suspension
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018542140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511465A5 (enExample
JP2019511465A (ja
Inventor
シャンタクマール・アール・チャヴァナギマット
クリス・ホルト
イン・タン
メリアラニ・エー・シー・エル・エス・アンダーソン
デニス・イー・フルビー
Original Assignee
シガ・テクノロジーズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シガ・テクノロジーズ・インコーポレーテッド filed Critical シガ・テクノロジーズ・インコーポレーテッド
Publication of JP2019511465A publication Critical patent/JP2019511465A/ja
Publication of JP2019511465A5 publication Critical patent/JP2019511465A5/ja
Priority to JP2021201709A priority Critical patent/JP7297858B2/ja
Application granted granted Critical
Publication of JP7074677B2 publication Critical patent/JP7074677B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018542140A 2016-02-16 2017-02-15 Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤 Active JP7074677B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021201709A JP7297858B2 (ja) 2016-02-16 2021-12-13 Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662295710P 2016-02-16 2016-02-16
US62/295,710 2016-02-16
PCT/US2017/017915 WO2017142910A1 (en) 2016-02-16 2017-02-15 St-246 ( tecovirimat monohydrate) suspension formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021201709A Division JP7297858B2 (ja) 2016-02-16 2021-12-13 Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤

Publications (3)

Publication Number Publication Date
JP2019511465A JP2019511465A (ja) 2019-04-25
JP2019511465A5 JP2019511465A5 (enExample) 2020-03-26
JP7074677B2 true JP7074677B2 (ja) 2022-05-24

Family

ID=59625432

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018542140A Active JP7074677B2 (ja) 2016-02-16 2017-02-15 Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤
JP2021201709A Active JP7297858B2 (ja) 2016-02-16 2021-12-13 Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021201709A Active JP7297858B2 (ja) 2016-02-16 2021-12-13 Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤

Country Status (8)

Country Link
US (2) US11433051B2 (enExample)
EP (1) EP3416637A4 (enExample)
JP (2) JP7074677B2 (enExample)
CN (1) CN108430469A (enExample)
AU (2) AU2017221295B2 (enExample)
CA (1) CA3013937A1 (enExample)
IL (1) IL260229B2 (enExample)
WO (1) WO2017142910A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022031345A (ja) * 2016-02-16 2022-02-18 シガ・テクノロジーズ・インコーポレーテッド Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049184A1 (en) 2016-09-09 2018-03-15 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
CN115141136B (zh) * 2021-03-31 2023-06-20 中国人民解放军军事科学院军事医学研究院 特考韦瑞药的共晶及其制备方法
JP7546138B2 (ja) * 2021-12-21 2024-09-05 上海奥全生物医葯科技有限公司 固形剤形を水に分散させて懸濁液を形成する方法、懸濁液および固体剤形を投与する方法
CN116625971A (zh) * 2023-04-11 2023-08-22 北京达因高科儿童药物研究院有限公司 一种西甲硅油口溶膜中二甲硅油和二氧化硅含量的检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011360A (zh) 2007-02-05 2007-08-08 深圳致君制药有限公司 干混悬剂的处方组成及其制备方法
CN102406617A (zh) 2011-11-30 2012-04-11 中国人民解放军军事医学科学院生物工程研究所 一种替韦立马干混悬剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043747A (en) * 1958-10-22 1962-07-10 Upjohn Co Tablets coated with carboxymethylcellulose shellac composition
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
ES2043766T3 (es) * 1987-11-11 1994-01-01 Pharmascience Lab Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua.
FR2705966B1 (fr) * 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
CA2793533C (en) 2010-03-23 2019-02-26 Siga Technologies, Inc. Polymorphic forms of st-246 and methods of preparation
CN102532901A (zh) 2010-12-21 2012-07-04 重庆北碚现代应用药物研究所 一种西甲硅油的制备方法
CN105055326B (zh) 2015-07-17 2018-02-06 西南大学 西甲硅油干混悬剂及其制备方法
AU2017221295B2 (en) * 2016-02-16 2022-05-19 Siga Technologies, Inc. ST-246 ( Tecovirimat monohydrate) suspension formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011360A (zh) 2007-02-05 2007-08-08 深圳致君制药有限公司 干混悬剂的处方组成及其制备方法
CN102406617A (zh) 2011-11-30 2012-04-11 中国人民解放军军事医学科学院生物工程研究所 一种替韦立马干混悬剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Virology，2005年，79(20)，pp.13139-13149

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022031345A (ja) * 2016-02-16 2022-02-18 シガ・テクノロジーズ・インコーポレーテッド Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤
JP7297858B2 (ja) 2016-02-16 2023-06-26 シガ・テクノロジーズ・インコーポレーテッド Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤

Also Published As

Publication number Publication date
JP7297858B2 (ja) 2023-06-26
EP3416637A1 (en) 2018-12-26
EP3416637A4 (en) 2019-11-06
CN108430469A (zh) 2018-08-21
WO2017142910A1 (en) 2017-08-24
IL260229B2 (en) 2023-06-01
IL260229A (en) 2018-07-31
US11433051B2 (en) 2022-09-06
US11779566B2 (en) 2023-10-10
AU2017221295A1 (en) 2018-07-12
AU2022218556A1 (en) 2022-09-15
JP2022031345A (ja) 2022-02-18
US20210212987A1 (en) 2021-07-15
CA3013937A1 (en) 2017-08-24
US20230016581A1 (en) 2023-01-19
AU2022218556B2 (en) 2024-08-15
AU2017221295B2 (en) 2022-05-19
JP2019511465A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
JP7297858B2 (ja) Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤
CN101778626B (zh) 含有瑞巴派特的药物组合物
MXPA06001481A (es) Jarabe en seco que contiene loratadina.
EP1128826B1 (en) Chromone enteric release formulation
WO2005009474A1 (ja) 難水溶性薬物を含むドライシロップ剤
CN104254249B (zh) 帕唑帕尼制剂
JP7359764B2 (ja) ジアミン誘導体を含む顆粒剤
JP2019530727A (ja) ラモトリギンを含む経口懸濁液用の粉末
JP2002193839A (ja) ココア製剤
JP2019514958A (ja) 遅延放出型経口用タムスロシン塩酸塩
Kulkarni et al. Design, development and scale up studies of metformin hydrochloride multiparticulate system: A promising alternative to large size tablet
ES2763321T3 (es) Premezcla y composición farmacéutica para la administración oral de memantina como una suspensión permanente o de preparación previa a la administración al paciente, optativamente por sonda de alimentación enteral y procedimientos correspondientes
US20110117193A1 (en) Antiretroviral drug formulations for treatment of children exposed to hiv/aids
TWI383809B (zh) 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
JP3837062B2 (ja) 難溶性薬物を含有する複合粒固形製剤
KR101458670B1 (ko) 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법
EP2558079B1 (en) Ciprofloxacin dry syrup composition
JP2025531270A (ja) ベルモスジルの液体製剤
Gabhane et al. Development of Dose Sipping Technology, a New Design Approach for Improving Drug Delivery of Acyclovir in Pediatric Medication
JP2024517874A (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の味マスキングされた組成物、及びそれを含む経口崩壊錠剤
KR20240004683A (ko) 알펠리십 제형
JPWO2018079734A1 (ja) メマンチンまたはその薬学上許容される塩を含有する医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220512

R150 Certificate of patent or registration of utility model

Ref document number: 7074677

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250